Clinical Medicine Department, Dermatology, Universidade Estadual de Londrina, Londrina, Paraná, Brazil.
Dermatology Department of São Paulo State University, Botucatu, São Paulo, Brazil.
PLoS Negl Trop Dis. 2023 Apr 5;17(4):e0010888. doi: 10.1371/journal.pntd.0010888. eCollection 2023 Apr.
The effect of leprosy on the sense of smell is not yet fully established. Studies that have relied only on patients' perceptions may have under- or over-estimated the change in smell perception. A validated and psychophysical method is necessary to avoid these errors in assessment.
This study aimed to validate the existence of olfactory involvement in leprosy patients.
A cross-sectional, controlled study was conducted, in which individuals with leprosy (exposed individuals) and individuals without leprosy (control patients) were recruited. For each exposed individual, we selected two control patients. A total of 108 patients (72 control patients and 36 exposed individuals) with no history of infection with the new coronavirus (COVID-19) took the University of Pennsylvania Smell Identification Test (UPSIT).
Most exposed individuals had olfactory dysfunction [n = 33, 91.7% (CI 95%: 77.5%-98.3%)] when compared with the control patients [n = 28, 38.9% (CI 95%: 27.6%-51.1%)], but only two (5.6%) had olfactory complaints. The olfactory function was significantly worse among exposed individuals [UPSIT leprosy = 25.2 (CI 95%: 23.1-27.3) when compared with the UPSIT control patients = 34.1 (CI 95%: 33.0-35.3); p<0.001]. The risk of olfactory loss was higher among the exposed individuals [OR: 19.5 (CI 95%: 5.18-105.70; p < 0.001)].
Olfactory dysfunction was highly prevalent among exposed individuals, although they had little or no self-knowledge of the disorder. The results show that it is important to assess the sense of smell in exposed individuals.
麻风病对嗅觉的影响尚未完全确定。仅依赖于患者感知的研究可能低估或高估了嗅觉感知的变化。为了避免评估中的这些错误,需要使用经过验证和心理物理的方法。
本研究旨在验证麻风病患者嗅觉受累的存在。
进行了一项横断面、对照研究,招募了麻风病患者(暴露个体)和没有麻风病的个体(对照患者)。对于每个暴露个体,我们选择了两名对照患者。共有 108 名(72 名对照患者和 36 名暴露个体)没有感染新冠病毒(COVID-19)病史的患者接受了宾夕法尼亚大学嗅觉识别测试(UPSIT)。
与对照患者(n=28,38.9%[95%CI:27.6%-51.1%])相比,大多数暴露个体(n=33,91.7%[95%CI:77.5%-98.3%])有嗅觉障碍,但只有两名(5.6%)有嗅觉抱怨。暴露个体的嗅觉功能明显较差[UPSIT 麻风病=25.2(95%CI:23.1-27.3)比 UPSIT 对照患者=34.1(95%CI:33.0-35.3);p<0.001]。暴露个体嗅觉丧失的风险更高[OR:19.5(95%CI:5.18-105.70;p<0.001)]。
尽管暴露个体对这种疾病知之甚少或一无所知,但嗅觉障碍在暴露个体中非常普遍。结果表明,在暴露个体中评估嗅觉是很重要的。